Science Signaling Podcast for 15 November 2016: A new type of kinase inhibitor

Hagit Eldar-Finkelman, Annalisa M. VanHook

Research output: Contribution to journalArticlepeer-review


This Podcast features an interview with Hagit Eldar-Finkelman, author of a Research Article that appears in the 15 November 2016 issue of Science Signaling, about a newly developed inhibitor of glycogen synthase kinase 3 (GSK-3). GSK-3 participates in several signaling networks and has been implicated in various pathologies, including neurodegenerative diseases, cognitive impairments, and cancer. Licht-Murava et al. developed L807mts, a substrate-competitive peptide inhibitor that blocks GSK-3 activity through an unusual mechanism. L807mts not only bound to the substrate recognition domain of GSK-3, it was also phosphorylated by the kinase. This phosphorylated form of L807mts remained associated with GSK-3 and inhibited GSK-3 activity. L807mts treatment reduced cellular, cognitive, and behavioral symptoms in a mouse model of Alzheimer's disease. L807mts is an advance in kinase inhibitor development because it is both highly specific and very potent.

Original languageEnglish
Article numberpc22
JournalScience Signaling
Issue number454
StatePublished - 15 Nov 2016


Dive into the research topics of 'Science Signaling Podcast for 15 November 2016: A new type of kinase inhibitor'. Together they form a unique fingerprint.

Cite this